New Delhi–Johnson & Johnson has agreed to pay up to $5.5 billion to resolve the remaining lawsuits alleging that its talc-based products caused ovarian cancer, provided at least 95% of eligible claimants participate in the settlement.
The proposed agreement covers remaining talc cases pending in U.S. federal and state courts, the company said.
Johnson & Johnson said the settlement follows a recent ruling by the federal multidistrict litigation court concerning whether plaintiffs could establish that the company’s talc products caused ovarian cancer in individual cases.
Under the proposal, the company would make an initial payment of up to $3 billion in 2027. No additional payments would be required before 2028.
The agreement is contingent on the participation of law firms representing at least 95% of the remaining ovarian cancer claims.
Johnson & Johnson said the proposed resolution complements earlier settlements covering about 95% of filed mesothelioma lawsuits, as well as state consumer-protection claims and disputes involving talc suppliers.
Erik Haas, Worldwide Vice President of Litigation at Johnson & Johnson, said the company continues to believe that the claims lack scientific merit but decided to pursue a settlement to bring the litigation to an end after about 15 years.
The company maintains that decades of research, clinical evidence and independent studies support the safety of cosmetic talc. It has also said its talc products did not contain asbestos and do not cause cancer.
Johnson & Johnson stopped selling talc-based JOHNSON’S Baby Powder globally in 2023 as part of a broader portfolio review.
The company also separated its consumer health business, Kenvue, that year but retained responsibility for talc-related liabilities.
The proposed settlement will take effect only if the required participation and other conditions are met. (Source: IANS)
